Trials / Unknown
UnknownNCT04326374
Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Visen Pharmaceuticals (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (GHD).
Detailed description
Not Provided
Conditions
- Growth Hormone Deficiency
- Endocrine System Diseases
- Hormones
- Pituitary Diseases
- Pituitary Disease, Anterior
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TransCon hGH | Once weekly subcutaneous injection |
| DRUG | daily hGH | Once daily subcutaneous injection |
Timeline
- Start date
- 2019-12-30
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2020-03-30
- Last updated
- 2020-03-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04326374. Inclusion in this directory is not an endorsement.